Visit to Suzhou Industrial Park by foreign representatives of the first China Pharmaceutical Innovation and Investment Conference

Source: China Council for the promotion of drugs 2016-11-16 on November 15, 2016, representatives of some embassies and consulates in China and international organizations attending the first China Pharmaceutical Innovation and investment conference in Suzhou visited Suzhou Industrial Park and Cinda biopharmaceutical (Suzhou), a member enterprise of China Council for the promotion of drugs Ltd and Suzhou Kangning Jierui Biotechnology Co., Ltd and went to the biomedical industry innovation center of the park for discussion and exchange In the morning of the same day, the delegation first came to Suzhou Biological Nanotechnology Park, the innovative biomedical industry development carrier of the park, visited the exhibition hall of the park, and learned about the innovation of the biopharmaceutical industry in the park Subsequently, the delegation visited Xinda biopharmaceutical (Suzhou) Co., Ltd and Suzhou Corning Jerry Biotechnology Co., Ltd., the leading innovative pharmaceutical enterprises in the park Zhou Qinwei, chief operating officer of Cinda pharmaceutical and Xu naidi, senior director of marketing department introduced the development process, phased innovation achievements and future development strategy of Cinda pharmaceutical, and discussed and exchanged international cooperation with representatives Xu Ting, CEO of Corning Jerry and Chen Jiandong, deputy general manager introduced the company's mission, vision, development process and innovation achievements, and accompanied the representatives to visit the company's R & D center Delegation visited the exhibition hall of Suzhou bio nano Park delegation visited Xinda bio delegation visited Corning Jerry that afternoon, delegation visited the planning exhibition hall of Suzhou Industrial Park, and had a discussion with the biomedical industry innovation center of the park Yin Jianguo, executive director of innovation center of Suzhou Industrial Park, introduced the development of biomedical industry in the park: Suzhou Industrial Park is one of the most innovative biopharmaceutical industry clusters in China, with more than 400 biomedical enterprises In 2015, the total output value of biomedical industry in the park reached 38 billion yuan, including 7.6 billion yuan of innovative pharmaceutical industry Up to now, there are 18 first-class new drugs in the park, including 6 new ones in 2016, showing a strong development momentum in the field of drug innovation Wang Xin, deputy director of China pharmaceutical promotion association, expressed his gratitude for the careful arrangement and strong support of the park, and hoped to continue to adhere to the tenet of "innovation, industrialization and internationalization", cooperate with Suzhou Industrial Park, embassies and consulates of various countries in China, international organizations, etc., and constantly promote multi-level and multi field international exchanges and cooperation in innovation investment in the pharmaceutical industry Discussion between the delegation and the innovation center of biomedical industry in the park Yuan yuan, project manager of International Department of China Council for the promotion of drugs, Duan Nan, business officer (Life Science) of commercial office of Canadian Embassy in China, Gu Yanping, business officer (Life Science) of Canadian Consulate General in Shanghai, Fang Qi, project manager of international trade and Investment Office of British Columbia government, Canada, and Shi Hui, senior business expert (medicine and health) of commercial office of American Embassy in China Ling, Kiyoshi Horie, Minister of Asia, International Committee of Japan Pharmaceutical Industry Association, Wang zhengxia, Senior Project Manager (medical and Life Sciences), Ying Lihua, senior official of the business investment office of the French Consulate General in Shanghai, Zhu Qingyu, senior business manager of the Australian Consulate General in Shanghai, Joshua Berlin, executive director of biocontry in the United States And so on.